Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Molecular Partners, with a price target of $13.00.

Robert Burns has given his Buy rating due to a combination of factors related to Molecular Partners’ advancing oncology pipeline and newly highlighted preclinical asset MP0632. He notes that MP0632, a logic-gated CD3 Switch-DARPin T cell engager targeting mesothelin and EpCAM, demonstrated the ability to selectively eliminate tumor cells co-expressing both antigens while substantially limiting activity on cells expressing only one, underscoring a potentially favorable therapeutic window.

Robert Burns’s rating is based on the view that MP0632’s “AND-gate” mechanism could deliver strong anti-tumor effects with reduced cytokine release versus earlier single-antigen T cell engagers, implying both superior efficacy and a safer profile in solid tumors such as ovarian cancer. He emphasizes that the program is not yet reflected in his current revenue model or valuation, so any successful clinical translation could provide meaningful upside to estimates, supporting his reiterated Buy rating and $13, 12-month price target for MOLN.